Verorab(R) Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years

Trial Profile

Verorab(R) Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Rabies vaccine (Primary) ; Rabies immune globulin
  • Indications Rabies
  • Focus Registrational; Therapeutic Use
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 1 Dec 2017 to 30 Oct 2018.
    • 28 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 30 Oct 2018.
    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top